SynthesisOncotarget2015

Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.

Tengfei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.